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Abstract
Background: Clinically protective malaria vaccines consistently fail to protect adults and children in endemic settings, and at
best only partially protect infants.
Methodology/Principal Findings: We identify and evaluate 1916 immunization studies between 1965-February 2010, and
exclude partially or nonprotective results to find 177 completely protective immunization experiments. Detailed
reexamination reveals an unexpectedly mundane basis for selective vaccine failure: live malaria parasites in the skin
inhibit vaccine function. We next show published molecular and cellular data support a testable, novel model where
parasite-host interactions in the skin induce malaria-specific regulatory T cells, and subvert early antigen-specific immunity
to parasite-specific immunotolerance. This ensures infection and tolerance to reinfection. Exposure to Plasmodium-infected
mosquito bites therefore systematically triggers immunosuppression of endemic vaccine-elicited responses. The extensive
vaccine trial data solidly substantiate this model experimentally.
Conclusions/Significance: We conclude skinstage-initiated immunosuppression, unassociated with bloodstage parasites,
systematically blocks vaccine function in the field. Our model exposes novel molecular and procedural strategies to
significantly and quickly increase protective efficacy in both pipeline and currently ineffective malaria vaccines, and forces
fundamental reassessment of central precepts determining vaccine development. This has major implications for
accelerated local eliminations of malaria, and significantly increases potential for eradication.
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Introduction
The malaria vaccine paradoxes
A solitary subunit vaccine marginally [1,2,3,4,5,6] protects children
in endemic areas [7,8] against malaria, and only partially protects
infants [9,10,11], similarly to malaria-naı ¨ve adults [12,13]. Adults in
endemic areas remain unprotected [14,15]. These data crystallize the
paradoxes central to 80 years of malaria vaccine research. Endemic
populations display T cell [16,17,18,19,20,21,22,23] and antibody
[24,25,26,27,28,29] responses to all malaria lifecycle stages and rapidly
acquire immunity to bloodstage parasites, mitigating adult disease and
death [29,30,31,32,33]. Immunity to earlier skinstage parasites
however does not develop, and endemic populations remain tolerant
to continual reinfection [32,33,34] remaining at risk for severe malaria
should immunocompetence weaken. Similarly, potentially protective
[17,35,36,37,38] T cell responses elicited by diverse attenuated-parasite
[20,39,40,41,42,43,44,45,46,47,48,49,50,51] and subunit [52,53,
54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69] malaria vaccines,
and laboratory infections [35,42,51,70,71,72,73,74,75,76,77] provide
sterile immunity [38,47,78,79,80] to infection, yet are ineffective in
endemic populations [14,15,81,82,83,84] and are effectively blocked
by the parasite [85]. Ostensibly, protection is blocked only in endemic
areas, implying a conditional difference between laboratory and field
infections which systematically triggers an immunological block to
vaccine function in the field. This rationale pinpoints an activatable
immune mechanism which blocks existing T cell responses. Obvious
candidates are the normal immune mechanisms suppressing autoim-
munity and allergy, or self- and nonself-tolerance. These mechanisms
centre largely around suppressive function of regulatory T cell subsets
(Tregs) [86,87]. Activated natural (nTreg) and induced (iTreg) Tregs
suppress effector T cell [86,87] and B cell responses [88,89,90,91,92]
and tolerize dendritic cells (DC) [93] to maintain self-tolerance and
regulate inflammatory responses to injury [94], tissue grafts [95,96,97],
pathogens and allergens [98,99,100].
A major regulatory immune organ, rich in regulatory T cells
[101,102], is human skin. This suggests the initial path of malarial
infection will profoundly affect systemic host responses to
subsequent lifecycle stages. Most experimental infections bypass
the skin entirely. Natural malaria infection however, starts in the
skin [103,104,105,106,107]. Infected mosquitoes inject motile
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migrate to proximal lymphatic vessels and skin-draining lymph
nodes (LN) [107]. Another few [107] invade blood vessels, rapidly
[109,110,111] migrating to the liver; the remainder linger in the
skin [107]. Liver invading parasites differentiate [112] and
multiply (for days) asymptomatically [32] until bloodstage-filled
vesicles bleb [113,114] into the blood, causing the systemic
inflammatory reaction [115], immunologically similar to sepsis
[115], underlying initial symptoms of clinical malaria. We
compile the immunobiology of Anopheline mosquito bites and
human skin, with the molecular and behavioural characteristics
of skinstage parasites, to show that natural infection leads
inevitably to systemic immunotolerance. We further show, via
comprehensive meta-analysis of fully protective vaccine trials,
that bypassing or disrupting natural parasite-host immune
interactions in the skin profoundly affects host responses to
vaccine antigens, and leads to protective immunization against
malaria.
Methods
Literature Searches for completely protective vaccine
trials, for meta-analysis
Searches were performed following MOOSE (Meta-analysis of
Observational Studies in Epidemiology) guidelines for conduct
and PRISMA (Preferred Reporting Items for Systematic Reviews
and Meta-analysis) reporting protocol for Systematic Reviews and
Meta-analysis [116]. Studies showing complete protection to
malaria challenge in mammals were identified by searching the
PubMed database (www.ncbi.nlm.nih.gov/pubmed/) with search
terms: malaria OR plasmodium & (complete &) protect* OR











White/Yoshida/Zavala/&/OR year (1965 – 2009). Searches were
performed by adding two or three qualifiers at a time to the basic
search string: [‘‘malaria’’ OR ‘‘plasmodium’’ AND protect*’’ OR
‘‘immuni*’’], and rerunning the search each time. We ran searches
without, then with, qualifier term ‘‘complete’’ to allow wide retrieval
sensitivity. Retrieved records werecombined and replicates removed.
Compiled single records were then screened by search term and
abstract perusal for traveller, bednet, thalassemia, genetic, pharma-
cokinetic, drug intervention, insecticide, repellent or mosquito
physiology content without reinfection follow-up, and excluded; we
also contacted authors to verify conditions where necessary. This
search strategy, (outlined in Figure 1), provided meticulous coverage,
as determined by random spot-checks for coverage. Last complete
database searches were carried out 9–13 September 2009; final
update searches were run 13 February 2010. We also examined cited
reference lists in studies and reviews identified. Late-breaking studies
were manually added to this final database.
Selection of studies for meta-analysis data–Inclusion/
exclusion criteria
Inclusion criterion: Identified full-text immunization studies
were then checked individually by full-text inspection for
experimental immunization and challenge conditions, and results
of challenge, and sorted with regard to complete protection criteria
(defined below). Immunization studies showing complete protec-
tion of all immunized subjects and infectivity in all control
infections (in any part of the study), were included in a final dataset
for analysis (Defined in Figure 1; listed in Table S1). No other
inclusion criterion was used. Studies in English, French, Spanish,
Portuguese and German were assessed, and sufficient discrimina-
tory data was available in English abstracts, for most studies
identified published in further languages. Studies in Oriental
languages without abstract (5) were not evaluated. Included studies
were further sorted for analysis according to experimental data as
described below in Validity and Sorting Criteria. Exclusion
criteria: Studies showing incomplete protection in immunized
subjects, or incomplete control infectivity, were excluded. No
other exclusion criterion was used on the immunization studies
identified by the search method described.
Figure 1. PRISMA Flow Diagram showing inclusion/exclusion
criteria for studies documenting complete protection 1965-
February 2010.
doi:10.1371/journal.pone.0010685.g001
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Complete protection criteria: bloodstage parasites undetectable
after challenge in all immunized subjects AND 100% of non-
immunized controls became parasitemic. Experiments document-
ing complete protection were further sorted into 8 categories, (a–
h), defined first by route and method of immunization, and then
route of challenge. Experimental data publications are listed by
category in Supplementary Table S1. The route and conditions
defining immunization in each category are represented graphi-
cally in Figure 2 (and in written form in Supplementary Table S2)
on green background, and explained in the legends to Figure 2
and Supplementary Table S2. The route of challenge, either
intravenous or via moquito bite, is indicated graphically on lilac
background, (in written form in Table S2) and explained in
legends for Figure 2 and Table S2.
Data Abstraction
Final database searches as described were performed separately
twice during a three month period (June-September 2009), and
once in February 2010, by the same person, and a further search
performed once by a second person. Four separate results
databases were combined with longterm manual search archives
from over 4 years, and replicates removed. Assessment of
compliance with complete protection criteria for the final dataset
was reconfirmed in all cases by one person. From this final dataset,
by full-text inspection, we retrieved specific experimental data
regarding method and route of immunization, and method and
route of challenge.
Analysis/Summary measures
We measured the percentages of our dataset of fully protective
vaccination experiments, that involved either absence, or pres-
ence, of live parasite interaction within the skin, during
immunization, during challenge, or during both.
Results
1. Selection of studies for vaccine trial meta-analysis
Literature search, final selection strategy and data retrieval were
designed to return data completely unlinked to and irrespective of
any criterion beyond complete protection. Searches targeted any
immunization, in any mammal, generating a comprehensive
database of immunizations from 1965-February 2010. Random
spot-checks confirmed meticulous coverage. Search method,
inclusion/exclusion, assessment and sorting criteria are fully
described in the Methods section. The probability of missing any
important immunization study is therefore finite but exceedingly
small. The probability of missing an entire class of vaccines is nil.
Literature searches and resulting datasets of factors contributing to
protective vaccine function were therefore comprehensive, and
completely unfocused and unbiased with regard to parasite life-
cycle stage, antigen character, proposed immune mechanism,
mode of application or any other criterion beyond complete
protection. Data for analysis (specific experimental data regarding
method and route of immunization, and method and route of
challenge) was included according to a rigorous definition of
complete protection.
We identify 1916 immunization studies performed worldwide
between 1965 and February 2010 (Fig. 1), and retrieve an
unambiguous, comprehensive and unbiased data set of 177
experiments in 161 publications documenting completely protec-
tive immunization, versus 1627 nonprotective or partially
protective immunization results (Fig. 1).
2. Vaccine trial data implicates the skin in vaccine failure
2-i. Meta-analysis shows complete protection against
natural challenge, by immunization via unmodified skin,
does not occur. Completely protective vaccinations (177
experiments, Fig. 2; see also Supplementary Table S2, and
Fig. 1) employing diverse vaccines, fall into 8 categories (Fig. 2a–h)
according to method, and routes of immunization and challenge.
These reveal that, unlike endemic populations (Fig. 2i), all
protected subjects (Fig. 2a–h, with verifiable exception of one
individual [117]) are malaria-naı ¨ve (unexposed to malaria-infected
mosquitoes) prior to first immunization (Fig. 2A). Most protective
vaccinations also physically bypass live parasite interactions in the
skin at either immunization or challenge (90%, Fig. 2B, a,b,c,e,h).
Bypass is either by intravenous (i.v.) injection, or use of dead
parasites, purified antibody or protein, or recombinant DNA, at
immunization (84%, Fig. 2a,b), or i.v. injection at challenge (84%,
Fig. 2a,c,e,h), usually by i.v. injection at both (78.5% Fig. 2a). Skin-
based immunization (via infected mosquito bite), completely
protective against virulent natural challenge (Fig. 2d,g) in
humans [118,119,120,121,122,123] and mice [124] occurs only
under conditions significantly altering the immune context in the
skin during immunization. These immunomodulary conditions are
illuminating and are examined in detail in Sections 3 and 4, and
entirely account for the remaining 10% of completely protective
immunization.
2-ii. Partially and non-protective studies strongly suggest
parasite skin interactions actively depress host
immunity. Otherwise, in mice, live-parasite immunization ‘‘via
the skin’’ (this includes subcutaneous injection (s.c.) which bypasses,
but inevitably contaminates, the skin) is usually non-protective
[125,126]. Where documented, skin-based immunization provides
complete [127] (Fig. 2f) or substantial [124,128,129] immunity only
against less infective Plasmodium berghei natural challenge, but not
against ,100-fold more infective [130] P. yoelii natural challenge
[127,128]. Intravenous immunization with P. yoelii protects
completely against intravenous challenge [128,129], but mosquito
delivered [128,129], or high-dose injected intradermal [128]
immunization does not. This suggests skin-immunization generates
immunity less efficiently [124,128], or increases intrinsic parasite
infectivity [124,128,131].
However, after identical intravenous infective challenge (by-
passing the skin) [128], diminished immunity with high dose skin
immunization (compared to intravenous) [128] must derive from
deficient host responses (activated less efficiently, or actively
depressed, or both), not parasite-intrinsic changes.
Therefore, since skin immunization with less infective [130] P.
berghei protects completely against intravenous infection (20,000–
50,000 parasites) [124,132], but not against a 20–200X lesser skin
challenge (10 bites) [124], (roughly 250–1000 parasites [107,110])
the data argue strongly for parasite-skin interactions increasing
host susceptibility by actively depressing host immunity.
2-iii. Immunity generated via unmodified skin is easily
broken. Intravenous mouse [128] and primate [68,133]
attenuated-sporozoite immunizations withstand repeated
intravenous challenge. Immunity generated by live parasites via
skin however, is reversed by small increments (5 additional bites,
or 125–500 more parasites) in natural challenge dose [124,128],
but withstands heavy intravenous challenge (20,000–100,000
parasites) [124,125,126,128,132] (see also Fig. 2c,e,h). Likewise,
skin-generated immunity in humans [119,134] (see also Fig. 2d)
despite immunizing doses 100-fold greater than challenge,
succumbs to increased [119,134], and usually, sequential
[119,123,134,135,136] natural challenge. Immunity generated
transiting skin, therefore, is marginal, and reversible.
Skin and Malaria Tolerance
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via the skin. Finally, intravenous immunization with bloodstage
parasites [76,77,137,138], fully protects against intravenous
bloodstage challenge in humans [77] and monkeys [137] and
both bloodstage [138,139] and sporozoite [76] intravenous, but
not mosquito-bite, challenge [138] in skinstage-naı ¨ve mice.
Similarly, major bloodstage-antigen vaccines (eg. MSP-142,
AMA-1), show strong antibody-correlated [61,67,140] efficacy
against symptomatic malaria after intravenous challenge in
monkeys [67,140] and induce similar antibody responses in
people from endemic areas [83,141,142]. Protective efficacy
against infection however, is negligible, despite some evidence of
reducing risk of symptom severity and parastaemia density
[143,144]. No bloodstage antigen in over 16 trials and 10,300
humans vaccinated to date, protects against infection by mosquito
bites [83,84,142,143,145,146,147] (and Figure 2i).
2-v. Summary: Vaccine trial data implicates the skin in
vaccine failure. Collectively, these data show that in malaria-
naı ¨ve subjects, (which excludes bloodstage immunosuppressive
effects) live-parasite immunization transiting unmodified skin is
inefficient. Immunity diminishes after unmodified skin-parasite
interactions and is significantly less robust generated via skin than
if intravenously. The bulk of experimentation shows immunization
avoiding parasite-skin interaction withstands heavy, repeated
intravenous challenge, but only limited challenge transiting the
epidermis. Importantly, the data imply parasite-skin interactions
Figure 2. Protective vaccination physically bypasses skin at immunization or challenge (90%) or involves skin immunomodulation
(10%). A. Exposure to parasites in the skin coincides closely with vaccine failure. Green background- immunization procedures. Lilac background-
challenge procedures and percent of total experiments showing complete protection (% total) formed by a subset of studies (category) using a given
experimental procedure (categories a-i; supporting data in references listed below). Inclined syringe- administration route is intravenous (i.v.) for live
parasites, or, the method does not involve live parasites, but uses dead parasites or purified antigen, antibody, or recombinant DNA (dead/Ag/Ab/
subunit) and therefore bypasses parasite interactions with host skin. Multiple mosquitoes- live parasites administered by multiple simultaneous
mosquito bites. Single mosquito- live parasites naturally transmitted by 4–15 bites. Mosquito in aromatic ring- live parasites administered by 12–15
bites/session with chloroquine. Vertical syringe- live parasites delivered subcutaneously (s.c) or intradermally (i.d.) or intramuscularly (i.m.); (i),
uncontrolled exposure to endemic mosquitos. B. Protective immunization physically bypasses the skin at either immunization or challenge in 90% of
cases (a,b,c,e,h). Protective immunization which transits skin during immunization (c,d,e,f,g,h) either: bypasses the skin physically at challenge (c,e,h);
or, involves skin immunomodulation during immunization (d,g, 10% of cases). Within A and B: Red lines and numbers- experiment bypasses parasite-
skin interactions at stage indicated by red lines; black lines and numbers- parasites interact with skin at stage indicated by black lines. Asterisk (*)-
immunization via unmodified skin, limited to less-virulent P. berghei (f). Skin bypass- method physically avoids live parasite interactions in the host
skin. Malaria exposure- skin exposure to infected mosquito bite before first immunization; naı ¨ve- no pre-exposure; exposed (endemic)- chronic
exposure. x- this study shows complete protection of 40 of 41 mice challenged. y: one person in one study [117] was infected one time via the skin




428,429,430,431,432,433,434,435,436,437,438,439,440,441,442,443,444,445,446,447,448,449,450,451]. b: [47,48,124,128,129,138,171,387,452,453]. c:
[124]. d: [36,44,118,119,120,121,122,123,124,134,135,136,172,454,455,456]. e: [111,132,457]. f: [127]. g: [163]. h: [48,111,388,458,459]. Studies containing
data for multiple relevant experimental conditions are referenced accordingly in each appropriate category. Multiple experiments contributed by a
single study are indicated beneath study reference number (eg. reference 124 X2) in Supplementary Table S1. (Meta-analysis data extended reference
list).
doi:10.1371/journal.pone.0010685.g002
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skin interactions during both immunization and challenge
however, associates solidly with immunity.
3. Altered immune context in the skin during
immunization protects against natural challenge and
suggests a skin-linked immunosuppressive mechanism
3-i. Immunization under pro-inflammatory skin
conditions confers protection. Complete human protection
with irradiation-attenuated [40,118,120,122,136] P. falciparum or
P. vivax requires 1000 or more mosquito bites [120,134] (usually
80–240 bites/session). This causes coalescing skin inflammation
[40,134], lasting several hours [134]. Immunity is reversed by
relatively small increases [119,134] in challenge dose, as for mice
[124,128]. Fewer total immunizing bites (,1000) are not reliably
[134], or (,700) not at all [52,135] protective when delivered in
low density bites/session [52,118,119,135], or with strongly anti-
inflammatory topical cream [40] and/or heavier parasite
irradiation [40,52]. However, 440 infected bites, delivered with
additional uninfected bites, increasing bite density, is protective
[123]. Rather than parasite dose alone [134,148], therefore,
protection appears influenced by degree of parasite attenuation
(limiting liverstages [149]), density of simultaneous bites, and pro-
inflammatory local context.
3-ii. Immunization via unmodified skin suppresses
available protective responses. Systemic proinflammatory
context confers resistance to malaria infection in mice
[150,151,152] and correlates strongly with human resistance
[153,154,155]. In uninflamed mouse skin, increasing immunizing
dose from 2 mosquito bites (roughly 50–200 parasites [107,110]) to
4 bites, significantly increases parasite-specific (CD8+) T cell
responses [79]. More immunizing bites yield no further increases
[79]. Yet, 100-fold higher immunizing doses (20 000 parasites)
delivered directly (i.v.) to the liver, provide almost twice the
protection of 10 000 parasites [47], proportionally increasing
specific T cell responses [79]. This reveals higher protective
responses to direct liverstage infection are available, which become
unavailable when parasites transit uninflamed skin. An
intravenous immunizing dose completely protective against i.v.
challenge of 20,000 parasites, but not against 10 bites [124] (20-
80-fold fewer parasites), is further consistent with skin-linked
immunosuppression.
These data suggest inflammatory skin context potentiates
immunization via skin, implying inflammation relieves a skin-
linked suppression of immunity to liverstage malaria unassociated
with prior bloodstage infection.
3-iii Skin-immunization under chloroquine (CQ)
immunomodulation also confers protection. CQ, a widely
immunomodulatory 4-aminoquinolone, accumulates preferentially
in human skin and lymphocytes [156], to levels 200–20,000 -fold
those in the liver, and remains in human skin, (not plasma) for 6
months [157]. Prophylactic in vivo concentrations (100–500 ng/ml
liver plasma [157,158]) inhibit antigen presentation in human
antigen-presenting dendritic (DC) and B cells in vitro
[159,160,161].
Immunization via skin with a drastically lower (but normally
100% infective [162]) dose of unattenuated P. falciparum (15
infected bites/session, x3), if co-administered with prophylactic
chloroquine (CQ), instead protects malaria-naı ¨ve individuals from
challenge (5 infective bites) [163]. CQ provides greater immunity
than parasite attenuation: considerably greater immunizing doses
of irradiated parasites without CQ do not protect mice [47] or
humans [134] against natural challenge. CQ treatment either
allows greater and/or antigenically broader immune responses
consequent to robust expression of liverstage antigens
[47,163,164], or lowers a barrier to immunity, or both. We
examine the evidence for both, below.
4. Protective effects of skin inflammation and CQ
immunomodulatory mechanisms implicate early, skin-
induced Tregs in systemic immunotolerance
4-i. The liverstage antigen concept for protective
immunity. That protection requires robust expression of
liverstage-antigens has significant correlative support.
Primaquine (PQ) eliminates all forms of liverstage parasites
[47,165] and concomitantly abrogates protection [165,166];
incremental parasite irradiation increasingly limits parasite
liverstage proliferation [149,165] and corresponds to decreasing
antigen synthesis [167] (implying decreased antigen presentation)
and diminished protectivity [165,167,168,169,170]. CQ
attenuation however, does not affect parasite liver stages [47],
allowing fullscale liver infections, abrogated after emerging from
the liver [47]. These data imply robustly expressed mid-
lateliverstage parasite antigens provide immunity [47,170] to
subsequent natural challenge.
4-ii. The liverstage antigen concept does not explain all
the data. Although widely accepted [163], this concept does not
reconcile important data. Genetically attenuated liverstage
parasites (p52/36, delivered i.v.), persisting in hepatocytes less
than 6 hrs [171] (minimizing antigen presentation) nonetheless
protect against stringent P. yoelii [171] natural challenge. Similarly,
protective responses to liverstage infection (delivered i.v.) are swift
[46,111], but do not increase with prolonged antigen presentation
[79]. Stable, protective [172] memory T cell populations to
skinstage parasites are induced and maintained by exposure to
sporozoite and bloodstage parasites in skinstage immunized,
(malaria-naı ¨ve) people [172]. Finally, endemic populations
remain susceptible to reinfection, despite multiple fullscale
liverstage infections, widespread use of CQ in adults, and
evidence for unimpaired development and recall of liverstage-
cognate memory responses during [80,173,174] and after [174]
bloodstage infection. These discrepancies suggest CQ co-
administered with skin-infecting parasites in malaria-naı ¨ve
people, confers protection in some way beyond allowing a
fullscale liverstage antigenic repertoire.
4-iii. CQ inhibits antigen presentation pathways vital to
Treg induction in skin. CQ disrupts all MHC II antigen
presentation [157,175,176] to CD4+ T cells. CQ also specifically
blocks [160] the rapid, seconds-to-15-minute [159] noncanonical
MHC I recycling pathway [160,161] for extracellular antigen
cross-presentation to cytotoxic (CD8+) T cells, which in human
plasmacytoid-DC (pDC) [160] enables very rapid cytotoxic
responses [160]. CQ does not block classical MHC I antigen
cross-presentation [161], which takes 6-18 hrs [160] for optimal
presentation.
Therefore, only slow, classical MHC I cross-presentation,
(efficiently functional in human skin-resident epidermal Langer-
hans DC (L-DC) [177,178], dermal DC (d-DC) [179] and other
immune and parenchymal cells [180] such as traversed [181] skin
or malaria-infected liver cells [111,182]), is available to generate
protective cytotoxic (CD8
+, MHC I) responses to malaria antigens
presented at the skinstage [18,28,183,184] in humans. In
agreement, protection provided by attenuated sporozoites against
intravenous challenge in mice, requires MHC I cross-presentation
[185]. Also, in humans, one therapeutic dose of CQ strongly
inhibits CD4+ T cell responses while strongly inducing CD8+
effector responses in vivo to a particulate viral antigen [186].
Malaria parasites constitute particulate antigen. Evidently, CQ
Skin and Malaria Tolerance
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earliest stages of malaria infection: the mosquito bite. Antigen-
specific responses dependent on rapid cross-presentation of
exogenous MHC I, and all MHC II antigen presentation,
including any regulatory T cell induction or activation, will be
blocked. CQ therefore, affects the balance of earliest host immune
responses triggered to malaria antigens, which are first encoun-
tered in the skin.
4-iv. Normal host response to mosquito-bite inflammation
triggers tolerizing cascades, facilitating parasite-cognate
Treg induction early in infection. Mosquito bites cause severe
local or systemic allergic inflammation [187], unless rapidly
dampened by in situ suppressive activity induced in antigen-cognate
T cells (iTregs) [91]. Human skin is rich (,100,000 per cm
2)
[101,102] in suppressive [102], skin-resident [101,102], circulating
[188,189] and LN-homing [102] nTregs, and local inflammation,
which recruits DCs and T cells [91,190] preferentially increases Treg
infiltration [91,191,192]. Tregs further accumulate at inflammatory
sites [91,193,194] via DC (antigen-presenting) dependent and
independent [102] mechanisms.
In skin, sunlight and allergen induced inflammations cause
keratinocyte signalling molecules [195] to interact with densely
interwoven epidermal [196] L-DC. This increases antigen
scavenging [195] in L-DC, and induces L-DC to generate de novo,
and proliferate, antigen-specific Tregs [195]. These skin-triggered
Tregs repress allergic inflammatory reactions both locally, in skin
and draining LNs, and systemically [195].
Mosquito saliva allergens [187], in sensitized subjects [152]
such as endemic populations also trigger [197] almost instanta-
neous [198] inflammatory extravasation [152,187,190], IgE-
mediated [199] and independent mast-cell TNF-a [190] and
local IFN-c and inflammatory cytokine secretion [152,187,190].
This induces chemokines [200] enabling [201] local skin
inflammations to rapidly recruit leukocytes [152,187,190],
including circulating immature monocyte-derived DC (mDC)
[200], pDC [200,202,203,204,205,206,207] not normally present
in skin, and skin-resident dDC and immature L-DC [200]. While
immature L-DC are initially tolerogenic [208,209,210], secreting
high levels of TGF-b [178,211], strong inflammatory stimuli
mature L-DC [178] to preferentially [178] crosspresent [177,178]
MHC I epitopes. This drives high avidity, antigen-specific
cytotoxic T cell responses against epidermally acquired antigens
[178]; human dDC preferentially stimulate antibody responses
[178].
However, in Anopheline mosquito-bites, infiltrating mast cells
rapidly degranulate [190], releasing stored TGF-b1 [212] and
bioactivating molecules [212], activating TGF-b signalling [213].
Exogenous bioactive TGF-b inhibits maturation and endogenous
antigen presentation by immature human L-DC after antigen
uptake [212,214], and upregulates IL-10 secretion in T cells [215]
and mDC [216] subsets (this includes L-DC [217]).
Immature human mDC [216,218,219,220,221,222] and antigen-
activated human pDC [222,223,224], (which also secrete chemokines
that attract circulating T cells [202]), prime IL-10-secreting,
immunosuppressive iTregs from interacting antigen-cognate T cells.
Suboptimal [225], or immature DC antigen presentation
[218,219,226] and low antigen dose [225,227,228] preferentially
[229] activate Tregs over effectors, and increasing local TGF-b and
IL-10 concentrations further activate Tregs [93,230,231,232]. This
tolerogenic cascade will act on recruited T cells and Tregs, potentially
including malaria-crossreacting specificities [233] present in malaria-
naı ¨ve people [55,77,234].
Once activated, nTregs also secrete bioactive [87] TGF-b1
[87,235,236,237], and most iTregs produce high levels of IL-10
[221,222,238,239] and/or TGF-b [194,222]. These cytokines mediate
multiple Treg activation [87,216,221,231,240,241,242,243], induction
[91,216,238,239,244,245,246,247] and suppression mechanisms both
antigen specific [95,231] and non-specific [87]. Also, independently of
DCs, accumulating human antigen-activated CD4+ Tregs can
themselves generate suppressive iTreg via TGF-b-dependent
[247,248,249] or IL-10 dependent [230,238] infectious tolerance.
Thesecascadingmechanismswillefficientlyexpand minisculenumbers
of cognate Tregs [93,100,247] initially activated or induced in location,
such as an Anopheline bite-site or draining LN.
4-v. Antigen presentation during mosquito bites provides
for opportunistic systemic subversion to malaria- specific
tolerance. Critically, Tregs normally home to inflamed tissue
[193] and LNs [250] according to homing molecules expressed
[251], and in inflamed skin [91,102,195] and LNs [252], rapidly
out-proliferate [252] and suppress priming [229,253] and
proliferation [252] of same-specificity effector T cells. Under
such Treg-dominated [88,254], or tolerogenic IL-10-rich
microenvironments [238,255], mature human mDC will also
generate iTregs [238,255,256]. This further facilitates specific
systemic tolerization to skin-encountered antigens. High,
tolerogenic IL-10 levels normally prevail within 8 hours in LNs
draining uninfected Anopheline mosquito bites [190,257]. The
normal response to Anopheline bites therefore, provides a
tolerogenically predisposed microenvironment, in which
parasites, when transmitted, will drive parasite-specific
tolerization.
Evidently, antigen presentation in skin during malaria-infected
mosquito bites provides major sources of antigen-specific Tregs
capable of repressing local [91,100], LN and systemic [195,258]
inflammatory reactions to bite-site antigens. T cell repertoires in
malaria-naı ¨ve people include malaria-cognate specificities
[55,77,234]. Malaria proteins contain amino acid sequences
highly conserved in human housekeeping proteins [233], implying
the pre-existence of malaria-cognate nTregs. These T cell and
Treg repertoires, responding to mosquito-allergen inflammation,
and the minimal malaria antigen doses transmitted in bites,
provide amply for de novo malaria-specific suppressive iTreg
generation, and expansion of pre-existing, potentially cognate
[233] nTregs, via Treg induction and expansion mechanisms
[225] documented in the basic literature (see above Section 4-iv).
Existing mechanisms for rapidly expanding Treg number
[221,222,225,249] and specificity spectrum [93] clearly support
rapid induction of antigen-specific Tregs and systemic tolerance
[93]. These conditions (part of the normal host response to
mosquito bites), occur in malaria infections at earliest skinstage,
well before bloodstages emerge. This facilitates opportunistic Treg
induction triggered at the skinstage by transmitted parasites. In
corroboration, in naı ¨ve animals, sand-fly transmitted skinstage
Leishmania parasites induce de novo parasite-specific Tregs (previ-
ously undetectable in the animal) [259] which inactivate robust,
protective cytotoxic responses [260] concomitantly elicited by
parasite infection. Conversely, and significantly, people in endemic
areas deficient in basic functions driving Treg induction (TGF-b
production, TGF-b receptors, FOXP3, CTLA-4) resist infection
[155], not just bloodstage disease, specifically implicating the
mechanisms of Treg induction and expansion described, in host
susceptibility.
4-vi. CQ specifically blocks Treg-inducing antigen
presentation: this prevents malaria-specific tolerance
induction via bite-site parasite interactions in the
skin. Skin-accumulating CQ disrupts bite-site antigen
presentation leading to Treg-induction and activation. Malaria-
naı ¨ve people treated simultaneously with CQ develop strong
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therefore, develops protection against natural challenge when
rapid cross-presentation of exogenous MHC I, and all MHC II
antigen presentation, and consequently also, major sources of
rapid antigen-specific activation and de novo induction of
tolerogenic CD4+ and CD8+ regulatory T cells in the skin and
skin-draining LN, are blocked at the skinstage during immunizing
skin infections. Slower, protective CD8+ responses to liverstages,
also primed in the peripheral lymph nodes [111,261] are
uninhibited. As seen (Section 4-ii), protection due to expression
of a broader liverstage antigen repertoire permitted by CQ, as
proposed by others [163] is inconsistent with lifelong susceptibility
in populations from endemic areas, and other, experimental data.
Therefore, live parasite immunization via the skin under CQ
immunomodulation, results in protection [163] because CQ
coadministered with naturally transmitted parasites, in malaria-
naı ¨ve people, effects an immunological bypass of rapid, initial
skinstage antigen-specific tolerization and suppression, enhancing
slower-developing immunity, and memory responses.
4-vii. Enhancing inflammation also counteracts
tolerization via the skin. Multiple-bite immunizations deliver
unnaturally high allergen/parasite-antigen doses, provoking
strongly pro-inflammatory microenvironments. Pro-inflammatory
conditions counteract [100,262], and inhibit [227,263] DC
tolerization and directly disrupt Treg-induction and activation in
mucosal skin [264], and can convert Tregs to effectors [265].
Multiple-bite immunizations therefore, support immediate,
predominantly cytotoxic [178] malaria-specific protective
immune responses, effectively disrupting skinstage tolerization,
and enhancing protective memory responses.
5. A role for the skin accommodates conflicting data
Consistent with this perspective, genetically attenuated immu-
nizing parasites, (p52/36 [171] or p36 [128]) administered
intravenously, entirely bypass skinstage interactions. Multiple
short immunizing liverstage infections, of sufficient dosage [171],
accumulate enough antigen exposure to establish protective
responses. Without inhibitory skinstage interactions, intravenous
immunization eliciting swift [46] limited [46,79] responses to
incipient liverstage infection will protect [79,266] against natural
challenge without antigen persistence [171,267], reconciling these
(and other [165,166], see Supplementary Text S1) contradictory
data.
In strong support, multiple cycles of intravenous infection and
subsequent elimination with primaquine (PQ), a parasiticidal drug
cure, administered during liverstage development (allowing limited
antigen presentation by infected hepatocyte [268] before PQ-cure)
builds robust protection to natural challenge [129]. Immunization
via skin, however, with identical PQ-cure cycles, reduces
protection [129] even against intravenous challenge, again
implicating the skin in inefficient development of immunity.
Finally, 56% [9] 266% [10,11] of infants (3–17 and 2–4
months old, respectively) from seasonal [269], high transmission
areas can be immunized against natural challenge [9,10] with a
skinstage antigen (CSP) vaccine, that negligibly protects, or does
not protect adults from endemic areas [14,15].
Adult endemic-region populations are largely pre-exposed
[270,271,272] to malaria parasites in the skin: high-transmission
areas provide over 2 infected bites per night [30,273,274].
However, neonates are skinstage malaria-naı ¨ve. Babies 0–6
months old, enrolled in medical trials, have significant chances
of being skinstage-naı ¨ve upon immunization, and remaining so for
3–6 months. Urbanizing environments [271], increased bednet use
(about 80% compliance [9]) and seasonal transmission relative to
birthdate, all reduce exposure to mosquitoes. This allows many
intramuscularly immunized infants to pre-establish robust protec-
tive responses before encountering skinstage parasites.
6. A critical role for immune mechanisms within the skin
in malaria vaccine malfunction
Chronic pre-exposure of skin to live parasites coincides closely
with failure of clinically functional vaccines (Figure 2A). Immu-
nization reliably protects against natural challenge only in
skinstage-naı ¨ve individuals where robust responses are established
before infective parasites ever interact with unmodified skin
(Figure 2b,d,g). Available epidemiological and vaccine trial data
strongly implicate the skin in a block to protective immunity
dependent on the presence of skinstage parasites and functional
CD4+ and rapid CD8+ exogenous-antigen presentation in the
skin, and independent of prior bloodstage infection. T cell memory
responses develop normally during [80,174,275] and after [275]
bloodstage infection, and human bloodstage-induced immunosup-
pression [276,277,278,279] is usually limited to acute malaria
[279,280,281]. The low incidence of acute malaria in semi-
immune [32,33] endemic adults cannot, therefore, account for
unmitigated susceptibility to reinfection, nor uniform inability of
diverse clinically functional vaccines to protect healthy, endemic
adults.
We conclude potentially protective liverstage and vaccine-
generated T cell responses, which indisputably exist, are disabled
by parasites in the skin.
7. Timing, behaviour and molecular characteristics of the
malaria parasite skin stage are aggressively tolerogenic
7-i. A role for the bite-site and parasite behaviour in early
systemic tolerization. Malaria-infected mosquito bites of 1
minute deposit around 20 [107] sporozoites in nanolitres [152] of
saliva into epidermal [107,110] and dermal [110] skin. Within an
hour, in mice, about 10–15% [107] (normally, 2–3) of deposited
sporozoites enter proximal skin-draining lymph nodes (LN)
[103,107,111], rapidly metamorphosing into bloodstage-like
forms [107], (we propose the term ‘‘pseudomorphs’’) expressing
antigens [107,282] characteristic of later liver and bloodstages
[282]. After 7 hours [107], most LN parasites are inside [107] or
entwined around CD11c+ [107] (cross-presenting) dendritic cells.
Some parasites (,10) remain in the skin [107], and their exact fate
is formally unclear. Antigens draining from these will initially
reflect the skinstage. However, host cell environment differentially
affects expression profile in malaria parasites [283,284]. Given the
metamorphic propensity of LN parasites, antigenic representation
of further lifecycle stages in skin-lingering parasites cannot be
excluded.
These data are crucial: they reveal the very earliest stages of
natural infection immediately expose the host immune system, via
skin and rapidly developing ‘‘pseudomorphs’’ in skin-draining LN,
to very low doses of (minimally) both skinstage and liverstage
antigens. These conditions anad location are highly conducive to
antigen-specific Treg induction and activation, and particularly
rapid induction of systemic tolerance [285], and therefore, rapid
systemic tolerance to parasite antigens arriving in the LN.
7-ii. Normal bite-site responses lead rapidly to systemic
tolerance. Tregs activated in skin bite-sites and LN by
migrating parasites and draining antigens will rapidly orchestrate
systemic tolerance. Tregs tolerize surrounding microenvironments
[88,100,254], downregulating mDC antigen presentation [286]
and upregulating mDC TGF-b and IL-10 secretion
[254,286,287]. This favours further Treg activation. Tregs also
reverse TLR activation of strong proinflammatory responses in
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ligands [289]. Contact with accumulating Tregs induces immature
human L-DC and mDC to remain semi-immature [286,287] and
migrate to draining LNs [287]. LN-migrating mDC can transfer
peripheral antigen to LN-resident DC [290] such as human pDCs,
which congregate in densely packed [291] naı ¨ve T cell regions
[292]. More immediately, pDC cross-presentation will induce IL-
10-secreting Tregs [223,224] in response to rapidly draining skin-
located antigens [291] (eg. from bite-site) and LN-migrating
parasite antigens, potentially within an hour of the mosquito bite.
Later arriving [293] semi-mature L-DC, trafficking antigen [293]
to naive T cell regions of the LN [294,295] will therefore
encounter pre-established, tolerizing microenvironments.
Accordingly, skin inflammations [296], Anopheline mosquito-
bites [190,257], and activated TNF-a producing mast cells [199],
all increase immature [296] L-DC migration and accumulation in
the LN [190,257,296]. Also, for isolated Anopheline mosquito
bites leukocyte infiltration [190] cross-presenting DCs [190]
carrying sporozoite antigen [111] and IL-10 concentration [257]
rapidly increase in draining LNs.
These data strongly suggest skinstage parasites capitalize on host
responses to isolated, uninfected Anopheline bites, (which are
normally immunosuppressive [257]), efficiently misdirecting sys-
temic responses to ensure tolerance to subsequently developing
parasites.
7-iii. Skinstage parasite molecules are intrinsically
tolerogenic. Malaria parasites also display aggressive
molecular intervention strategies. Critically, gliding sporozoites
[297] transiting skin cells [298,299] the LN lumen [107] and
invading LN DCs [107], will shed circumsporozoite protein (CSP)
and thrombospondin-related-adhesive protein (TRAP) [297,300].
Cytoplasmic CSP, shed by infecting parasites, inhibits host
transcription activator NF-Kb [301], strongly downregulating
multiple pleiotropic pro-inflammatory (anti-parasitic [302])
activities including IL-6 [301] during plasmodial liver infection.
It is well established in non-malarial systems that IL-6 averts
CD4+ iTreg formation [303,304,305,306] and crucially,
suppresses the antigen-specific CD4+ Treg activity [307,308],
which inhibits both T cell activation to foreign antigen [307] and
CD4+ and CD8+ T cell memory development [308,309]. This
directly infers IL-6 blockade by malarial CSP [301] prevents
immediate protective T cell activation and memory responses in
the skin, LN and infected hepatocytes, simultaneously stimulating
in these locations antigen-specific Treg formation
[303,304,305,306,310,311] and expansion [305], triggered by
malaria antigens. This will limit any malaria-specific responses
arising. Accordingly, immediate in vivo T cell responses to malaria-
infected hepatocytes [46] are ‘‘self-limiting’’ [79,266], and
plasmodial liver infection, (an extensive tissue insult), is non-
inflammatory and asymptomatic [114]. Further, high dose
antigen-presentation, which counteracts Treg suppression [227],
in the case of malaria-antigens [312] relieves self-limitation of
malaria-specific responses [312], implicating malaria-specific
Tregs in self-limiting immune responses to infected hepatocytes.
Also, P. falciparum TRAP (expressed in both skin and blood
stages [313]), like human thrombospondin, bioactivates latent
human TGF-b [314] via the TSR-1 domain [315]. Thrombos-
pondin, by a TGF-b-dependent [316] mechanism [212,239],
converts cognate CD4+ T cells into suppressive iTregs in situ [316]
conferring localized tissue tolerance in mice [316]. In humans,
parasite-driven TGF-b bioactivation [314,317] precedes and
correlates strongly with significantly increased Treg numbers
and parasitaemia densities [317], and suppresses proinflammatory
responses in humans [317] and mice [318]. In unimmunized mice,
co-inhibition of TGF-b and IL-10 early [318] in infection, or
depletion of Treg [319], restores proinflammatory responses and
parasite clearance. Correlative, functional data therefore strongly
suggest Treg-inducing skinstage function for TRAP molecules.
7-iv. Skinstage parasite behaviour is potently
tolerogenic. Human allergen therapy boosts antigen-specific
systemic tolerance by chronic low doses applied via the skin
[285,320], and requires Treg induction and activation [258,320].
Tolerization is drastically accelerated by low-dose antigen
frequently introduced directly into skin-draining LNs [285].
Similarly, people constantly exposed to infected bites inevitably
collect frequent low numbers of CSP/TRAP-shedding, LN-
migrating, and skin-lingering ‘‘pseudomorphic’’ parasites. This
directly infers parasite instigation of continuous Treg activation
and induction in both skin and LN, and inevitably, potent
intralymphatic, antigen-specific systemic tolerization to exposed
malaria antigens.
8. A model for skinstage-initiated immune subversion
incorporates normal immunobiology of Treg induction
and mechanism, and the cadence, behaviour and cellular
biology of the parasite lifecycle stages
8-i. The model. Cellular and molecular data indicate isolated
malaria-infected mosquito bites drive rapid systemic tolerization to
malaria antigens at the skinstage. Since naturally transmitted
parasites progress from skin to liver to blood, liver infections
inevitably present malaria sporozoite [182,268] and liverstage
antigens to an already efficiently compromised host immune
system.
Tregs from human skin are highly proliferative in vivo, develop
alongside effector responses at the site of a skin inflammation
[321], and can be induced in vivo and ex vivo from highly
differentiated memory T cells, by antigen reencounter [321,322].
Tregs in vivo are preferentially [102,228] induced and activated,
and have an in vivo proliferative advantage [102,252,323] over
non-Tregs. These properties provide a clear systemic advantage to
any suppressive malaria-specific Tregs generated at the skinstage,
over simultaneously elicited malaria-specific [111] protective
cytotoxic T cell responses.
Skinstage pre-exposure of later life-cycle antigens [107] provides
an additional temporal advantage: liverstage infections subse-
quently presenting CSP [268] and pre-exposed liverstage epitopes
(eg TRAP, EXP-1) will enhance pre-established parasite-protective
Treg populations, suppressing swift cytotoxic responses initiated
against infected hepatocytes. B cells require activated T cell help to
initiate IgG antibody responses, and Tregs will also directly,
antigen-specifically and non-specifically, inhibit or kill activated B
cells [89,90,92,324]. Antibody responses and B cell function will
therefore also be vulnerable to repression by skin-induced,
malaria-specific Tregs, from the skinstage onwards. Infection,
and reinfection, not sterile immunity, will prevail in natural
transmission.
Induction of broad-spectrum malaria-specific Tregs in the skin
therefore, ensures liverstage infections always develop into
transmissible blood stages. At least 281 bloodstage proteins are
expressed at the skin stage, including AMA-1, PfEMP and
STEVOR proteins [325]. More than one liver- and bloodstage-
expressed antigen (eg TRAP, EXP-1) [313,326,327] is definitely
exposed at the skinstage [107,313], and therefore to the skin-based
tolerizing mechanisms we define. Once Tregs are induced, numerous
mechanisms (see Sections 4-iv, 4-v, 7-iii) exist allowing small numbers of
Tregs of one specificity to expand, outgrow, convert non-Tregs of different
specificities to suppressive function (infectious tolerance), and also non-
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Therefore, a Treg response specific and suppressive to one
liverstage or bloodstage antigen (eg. TRAP or EXP-1), triggered
initially during skinstage, can later re-expand upon specific antigen
re-encounter at the liver or bloodstage, and non-specifically
suppress T cell (or ablate memory B cell) responses to further
parasite antigens co-expressed only at the later stage, eg. responses
to MSP-1, specific to late-liver and bloodstages. Pre-induction of
bloodstage-specific Tregs provides an obvious protective advan-
tage promoting the establishment of bloodstage parasites emerging
from the liver. Re-expansion of pre-induced Tregs will initiate a
tolerogenic cascade and immunosuppressive environment condu-
cive to bloodstage expansion, which is further enhanced by the
bloodstage parasite themselves. Bloodstage parasites generate Treg
activity [317,319,328,329] and nonspecific immunosuppressive
conditions [85,314,329,330,331,332], enhancing systemic toler-
ance [328,333] conducive to multiple parasitaemia cycles, thereby
increasing probability of gametocyte transmission, and also
reinfection [85,334].
8-ii. Model outcomes: experimental versus field
infections. Experimental, intravenous sporozoite infections
bypass skin/LN Treg activation (Figure 3B). Consequently,
predominant immune responses to liverstage infection, which
prime in the peripheral LN [111,261] are unhindered, rendering
the immunodominant CSP molecule and also TRAP,
experimentally protective [335,336,337].
Like physical bypass of immune interactions in the skin at
immunization or challenge (Fig. 3B), immunological bypass by CQ
inhibition of antigen presentation (Fig. 3C), or inflammatory
inhibition of tolerizing cellular cascades (Fig. 3D) during
immunization, consistently result in protection to natural skinstage
challenge for malaria-naı ¨ve subjects.
Natural, skin-initiated infections however, pre-establish antigen-
specific tolerance to parasite antigens presented in the skin and LN
(Fig. 3A). In fundamental opposition to current opinion [338] and
vaccine dogma, this model shows CSP and TRAP are pleiopo-
tently immunosuppressive molecules when deployed within the
cadence of natural infection. Other lifecycle-stage antigens pre-
exposed by skinstage ‘‘pseudomorphs’’ [107], such as liver and
bloodstage antigens, broaden the scope of immunosuppressive
systemic responses to parasite antigens subsequently encountered
during liverstage or bloodstage infection (or immunization).
Critically, again directly opposing prevailing opinion, further
exposure to infected mosquitoes will boost tolerance, and
suppression of protective responses, not immunity.
8-iii. Selective vaccine failure: who, where and why. Adults
chronically exposed to infected mosquitoes from birth will
accumulate broad repertoires of regulatory T cells, becoming
potently pretolerized. Vaccination deploying skinstage-exposed or
bloodstage antigens will activate both pre-existing cognate Tregs
[225,252,339] as shown for foreign antigen in mouse systems, and
malaria-specific T cells, (effector and other subsets) as shown in
humans [340,341]; challenge by mosquito bite will preferentially
boost pre-existing Treg-based tolerance [225,339], suppressing
protective concomitantly elicited and recall responses [339].
Vaccines which substantially protect malaria-naı ¨ve adults [12,13]
will negligibly, or not, protect endemic-area adults [14,15], as solidly
evidenced by adult vaccine field trials.
Neonates, initially skinstage-malaria-naı ¨ve, are easier to protect
from mosquito bite. Accumulation of skinstage-induced regulatory
T cells specific for malaria will be negligible, and immunization
will (potentially unrestrictedly) favour [69] immunity. Endemic-
area infants, like malaria-naı ¨ve adults, should be better protected
by formulations that negligibly protect endemic-area adults. This
profile is precisely corroborated by results for leading CSP-
containing RTS,S, vaccine formulations. These protect malaria-
naı ¨ve adults partially [12,13], endemic-area infants (2–17 month-
old) similarly partially [9,10,11], older children poorly [7,8,342]
and endemic-area adults negligibly [1,14,15].
Discussion
Limitations of the study
Using rigorous systematic literature search, and individual
screening with unambiguous criteria on nearly 2000 studies, we
have identified the great majority of peer-reviewed, experimental
evidence documenting complete protection to malaria infection.
Meta-analysis of experimental conditions involved shows only
immunizations that avoid live parasite interaction in the skin, or
inhibit regulatory T cell induction within the skin during skin-
immunization, fully protect against infected mosquito bites. Our
main conclusion, that very early, skinstage-induced, antigen-
specific regulatory T cells block malaria vaccine function therefore
rests empirically but solidly on a straightforward meta-analysis of
unbiased experimental data. The data were retrieved from
experiments carried out worldwide, by hundreds of groups, using
many different protocols over many decades, and drawn from
extensive literature reporting skinstage, liverstage and bloodstage
vaccine trials. This minimizes both experimental bias and the
impact inherent in overlooking any one published study, but does
not specify a mechanism. However, detailed molecular/cellular
immunological data from experiments carried out independently,
in the main by basic research groups unconcerned with malaria
(and therefore unbiased), define a mechanism of tolerogenic
induction via the skin which strongly supports this conclusion.
Combined with the cadence of the parasite lifecycle stages, and the
behaviour and detailed cellular and molecular character of
skinstage parasites during transmission, we define a novel
immuno-epidemiological model for vaccine success/failure. This
identifies differential exposure to infected mosquitos and malaria-
specific Treg accumulation as the basis for selective vaccine failure
in endemic-area populations, and defines a skin-triggered
immunological mechanism for early tolerance induction, preced-
ing and independent of later bloodstage immunosuppression. The
available epidemiological and experimental vaccine trial data are
entirely consistent with the immunological mechanism and model
we propose. The model specified by these combined data easily
explains myriad long-standing incongruities, paradoxes and
contradictions in the malaria literature. In 1916 studies, we could
find no experimental immunization or natural infection data
which contradict or weaken our conclusions.
Fundamental implications for vaccine efficacy
Circumvention of malaria-specific regulatory T cell activation in
the skin fits all identified instances of protective immunization
against virulent experimental challenge, and selective protection in
endemic skinstage challenge. Fundamental immediate and long-
term implications for vaccine development and strategy are
highlighted below.
i. Live parasite vaccines. Unmodified intradermal delivery
[148] will obliterate efficacy in otherwise outstandingly successful
attenuated-parasite vaccines, advocating optimization of immune
context for dermal delivery.
ii. Antigen selection. Intrinsically tolerogenic antigens (eg.
CSP, TRAP), or those enriching skinstage and/or bloodstage-
cognate Tregs (eg. TRAP, EXP-1), (or abundant bloodstream
antigens, eg. AMA-1, MSP-1, which will almost inevitably induce
homeostatic regulatory T cell activity), are counter-productive in
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PLoS ONE | www.plosone.org 9 May 2010 | Volume 5 | Issue 5 | e10685Figure 3. All protective immunization circumvents initial malaria-specific Treg activation in the skin: a functional model. A: Natural
transmission (mosquito bite) allows skinstage parasites (sporozoites, spz, green fragments) to migrate (dotted gray arrows) through skin cells to both
lymph nodes (LN) and liver (via blood vessels, bv), and induce malaria-specific regulatory T cells in the skin and LN that suppress (red blocker lines)
local and systemic protective immune responses (green arrows), resulting in bloodstage infections (gray fragments below liver), and amplification
cycles within red blood cells (rbc). B, C, D: Protective immunity develops where immunization and/or challenge avoids parasite-skin interaction and
Treg activation/induction; B: Physical bypass of the skin, (by intravenous (i.v.) attenuated parasites, purified antigen, antibody or intramuscular or
intranasal subunit vaccine) at immunization, or i.v. challenge with unattenuated infective parasites, avoids all induction or activation of skin and
liverstage-specific Tregs. C: Chloroquine (CQ) accumulates and blocks all MHC II and rapid, (but not classical, slow) MHC I malaria-antigen
presentation in the skin, which would otherwise immediately induce/activate antigen-specific Tregs. D: Multiple simultaneous mosquito bites create a
strongly pro-inflammatory local skin and/or systemic milieu which inhibit Treg activation and induction processes. LN Inset: Inside LN,
metamorphosing skinstage sporozoite parasites (spz) are in close contact with, or invade, host antigen presenting dendritic cells (DC).
doi:10.1371/journal.pone.0010685.g003
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naı ¨ve individuals, such as neonates. With age, increasing bite
exposure and skin-induced malaria-specific Treg accumulation
will repress T cell and B cell responses, eroding [90,92] skinstage-
specific, antibody-correlated [10,343,344,345] infant protection
elicited by leading vaccines such as RTS,S. Of particular concern,
vaccination with intrinsically tolerogenic antigens although
initially protective in malaria-naı ¨ve infants, will also predispose
bite-exposed growing children to severe malaria, increasing
individual risk of later childhood death. Late-midliverstage
antigens (unexposed at skinstage) however, should initially escape
significant Treg induction and memory inhibition in the skinstage,
and do show protectivity [17,26,27,68,346,347] into adolescence
[347]. This makes late-midliverstage antigens rationally preferred
candidates for more universally applicable subunit vaccines with
less hindered immune memory.
iii. Infant mortality. Neonates protected from mosquitoes will
not accumulate skinstage-specific Tregs. Immunization under Treg
pre-emptive conditions from birth (non-tolerogenic antigen, CQ
accumulation in the skin, scrupulous useof bed-nets/insect-repellent),
inducing abundant skinstage-specific antibodies should substantially
reduce infant infections beyond currently obtainable protection.
Additional early-infancy immunization with liverstage [347] and
bloodstage antigens [29,30] will rapidly [29,30,33,348,349] provide
robust [29,30] bloodstage immunity. This provides critical protection
against increased risk of severe malaria [274] due to decreased
exposure to bloodstage disease. Substantially reduced childhood
morbidity and mortality, and shrinking transmission reservoirs,
should result.
iv. Eradication. Discarded vaccines, ineffective in endemic
adults but pretested for safety, immunogenicity and tolerability can
be rapidly retested (given voluntary patent rescindication [350]) for
protectivity in neonates under Treg pre-emptive conditions.
Bednets and CQ are cheap, CQ is usually well-tolerated,
including during pregnancy [158,351], and is transmitted
transplacentally at therapeutic doses and via breast milk at
subtherapeutic dosages [351]. CQ accumulates preferentially in
the skin, so significantly reduced, subtherapeutic dosage may
suffice. Treg-blocking (immunomodulary) pharmacological effects
of CQ are on the host, not parasite, eliminating parasite-resistance
obstacles. Current infrastructure (http://www.theglobalfund.org)
allows largescale immunization across (primarily African) endemic
regions worldwide.
Malaria outside Africa is mostly hypoendemic [270], and not all
Africa is holoendemic [270]. With increasing bednet/insecticide
use, transmission drops [270,272,352,353]. Coordinated neonate
vaccination generating additional concerted widespread reduc-
tions (herd effects) in infectious reservoirs is feasible, even with low
efficacy vaccines [354]. Conditions pre-empting Treg induction at
early skin stage will amplify trends leading to interrupted
transmission, catalyzing [272] significantly accelerated local
elimination, and facilitating worldwide eradication of malaria.
Existing adult transmission reservoirs however, will counteract
shrinking infant reservoirs [272,354]. Skinstage-induced-Treg
evasion and memory enhancing vaccines, preventing adult re-
infection, and transmission-blocking vaccines targeting parasite
development within the mosquito, and antimalarials blocking
bloodstage transmission, are therefore essential to fast-track
eradication.
Wider perspective
Skinstage activation of parasite-specific Treg-based systemic
immunosuppression provides a fundamentally new, experimental-
ly widely substantiated, immunological rationale, and precise
focus, for research and vaccination strategy leading to potentially
accelerated malaria eradication. The concept, and implications for
vaccination, apply to closely related and economically important
(Toxoplasma, Theileria, Babesia spp.) pathogens.
Supporting Information
Table S1 Complete protection data (177 experiments) reference
list for meta-analysis.
Found at: doi:10.1371/journal.pone.0010685.s001 (0.24 MB
DOC)
Table S2 Protective vaccination physically bypasses the skin at
immunization or challenge (90%) or involves skin immunomod-
ulation (10%). A. Exposure to parasites in the skin coincides closely
with vaccine failure. Green background- immunization proce-
dures. Lilac background- challenge procedures and percent of
total experiments showing complete protection (% total) formed by
a subset of studies (category) using a given experimental procedure
(categories a-i; supporting experimental data for each category is
in references listed below; also Supplementary Table S1). Parasite
immunization administration routes: (a,b): live parasites given
intravenously (i.v.), or the method does not involve live parasites,
but uses dead parasites or purified antigen, antibody, or
recombinant DNA (subunit) and therefore bypasses parasite
interactions with host skin; (c,d,e,f,g,h): live parasites are
administered via the skin; (c,d): by multiple simultaneous mosquito
bites/session; (e,f): live parasites are naturally transmitted by 4–15
bites; (g): live parasites are administered by 12–15 bites/session
with chloroquine; (h): live parasites delivered subcutaneously (s.c)
or intradermally (i.d.) or intramuscularly (i.m.); (i): uncontrolled
exposure to endemic mosquitos. Challenge route is either i.v. or by
mosquito bite, as indicated. B. Protective immunization bypasses
the skin at either immunization or challenge in 90% of cases:
categories (a,b,c,e,h) shaded blue with red crosses. Protective
immunization which transits skin during immunization (c,d,e,f,g,h)
either: bypasses the skin physically at challenge (c,e,h) (red cross);
or, involves skin immunomodulation during immunization (d,g,
10% of cases). Asterisk (*)- immunization via unmodified skin,
limited to P. berghei (f). Skin bypass (red cross)- method physically
avoids live parasite interactions in the host skin. Malaria exposure-
skin exposure to infected mosquito bite before first immunization;
naı ¨ve- no pre-exposure; exposed (endemic)- chronic exposure. x-
this study shows complete protection of 40 of 41 mice challenged.
y: one person in one study [117] was infected one time via the skin
prior to protective immunization and was therefore moderately










48,124,128,129,138,171,387,452,453]. c: [124]. d: [36,44,118,
119,120,121,122,123,124,134,135,136,172,454,455,456]. e: [111,
132,457]. f: [127]. g: [163]. h: [48,111,388,458,459]. Studies
containing data for multiple relevant experimental conditions are
referenced accordingly in each appropriate category. Multiple
experiments contributed by a single study are indicated beneath
study reference number (eg. reference 124 X2) in Supplementary
Table S1. (Meta-analysis data extended reference list).
Found at: doi:10.1371/journal.pone.0010685.s002 (8.70 MB TIF)
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protection. Directly contradictory data [165,166,171,267] is also
easily reconciled. Like increasing irradiation [149,165], the drug
primaquine (PQ) eliminates liverstages [47,166]. PQ however, also
disrupts membrane and vesicular trafficking [159,268], temporar-
ily eliminating all antigen presentation. This prevents immunity if
used during immunization [166], creating an apparent correlation
between protection and parasite persistence [166]. Used after
intravenous immunization [129], allowing early liverstage antigen
presentation, however, multiple PQ-cure cycles provide sufficient
cumulative antigen presentation to build immunity, without
antigen persistence.
Found at: doi:10.1371/journal.pone.0010685.s003 (0.07 MB
DOC)
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